11/10
07:59 am
caba
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/10
07:55 am
caba
Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]
Medium
Report
Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]
11/10
07:30 am
caba
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
11/4
07:01 pm
caba
Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]
Low
Report
Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]
11/4
08:00 am
caba
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Medium
Report
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
10/31
09:52 am
caba
Cabaletta Bio (NASDAQ:CABA) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $30.00. They now have an "overweight" rating on the stock.
High
Report
Cabaletta Bio (NASDAQ:CABA) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $30.00. They now have an "overweight" rating on the stock.
10/27
07:00 am
caba
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
High
Report
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
10/14
08:00 am
caba
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
High
Report
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
10/10
10:13 am
caba
Cabaletta Bio (NASDAQ:CABA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $14.00 price target on the stock.
High
Report
Cabaletta Bio (NASDAQ:CABA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $14.00 price target on the stock.
10/10
08:06 am
caba
Cabaletta Bio (NASDAQ:CABA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
High
Report
Cabaletta Bio (NASDAQ:CABA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
10/9
12:00 pm
caba
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
High
Report
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
10/7
06:23 am
caba
Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon [Seeking Alpha]
Medium
Report
Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon [Seeking Alpha]
9/18
10:06 pm
caba
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment [Yahoo! Finance]
Low
Report
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment [Yahoo! Finance]